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Available online 28 April 2017Itmay be challenging to distinguish autoimmune encephalitis associatedwith anti-neuronal autoantibodies from
primary psychiatric disorders. Here, serumwas drawn from patients with a first-episode psychosis (n=70) or a
clinical high-risk for psychosis (n=6) and controls (n=34). We investigated the serum prevalence of 24 anti-
neuronal autoantibodies: IgG antibodies for anti-N-methyl-D-aspartate-type glutamate receptor (anti-NMDAR),
glutamate and γ-aminobutyric acid alpha and beta receptors (GABA-a, GABA-b), alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPA), glycine receptor (GlyR), metabotropic glutamate receptor
1 and 5 (mGluR1, mGluR5), anti-Tr/Delta/notch-like epidermal growth factor-related receptor (DNER),
contactin-associated protein-like 2 (CASPR2), myelin oligodendrocyte glycoprotein (MOG), glutamic acid decar-
boxylase-65 (GAD65), collapsin response mediator protein 5/crossveinless-2 (CV2), aquaporin-4 (AQP4), anti-
dipeptidyl-peptidase-like protein-6 (DPPX), type 1 anti-neuronal nuclear antibody (ANNA-1, Hu), Ri, Yo,
IgLON5, Ma2, zinc finger protein 4 (ZIC4), Rho GTPase-activating protein 26, amphiphysin, and recoverin, as
well as IgA and IgM for dopamine-2-receptor (DRD2). Anti-NMDA IgG antibodies were positive with serum
titer 1:320 in one patient with a clinical high risk for psychosis. He did not receive a diagnosis of encephalitis
after comprehensive neurological evaluation. All other antineuronal autoantibodies were negative and there
were no additional findings with immunohistochemistry of brain issues.
© 2017 Elsevier B.V. All rights reserved.Keywords:




Clinical high risk of psychosis
First episode psychosis1. Introduction
Anti-N-methyl-D-aspartate-type glutamate receptor (anti-NMDAR)
encephalitis was originally identified in youngwomenwith ovarian ter-
atoma who had simultaneous prominent psychiatric manifestations.
Later, it was noted that anti-NMDAR encephalitis can manifest without
cancer (Dalmau et al., 2008), and some cases present with prominent
psychotic symptoms (Kayser and Dalmau, 2016; Pollak et al., 2016).
Clinically, patients with psychosis and IgG anti-NMDAR antibodies areuglas Mental Health University




ker), b.teegen@euroimmun.decharacterized by acute or subacute onset, catatonic symptoms, epilepsy
and movement disorders including stereotypies, perseveration, and
dystonia, or fever. Several other anti-neuronal antibodies targeting im-
portant ion channels, receptor-associated or regulatory molecules
have been reported in some patients with psychosis and in patients
with encephalitis presenting psychotic symptoms (Armangue et al.,
2014; Heine et al., 2015; Leypoldt et al., 2015; Pollak et al., 2016). The
prevalence of these antibodies in patients with an early psychosis re-
mains open. The identification of encephalitis in patientswith early psy-
chosis is crucial, as over 75% of patients with classic anti-NMDAR
encephalitis have substantial recovery with specific treatments, while
antipsychotic treatment is not effective in these patients (Kayser and
Dalmau, 2016).
In a sample of patients with a first-episode psychosis (FEP) or a clin-
ical high-risk for psychosis (CHR) and controls, we investigated the
prevalence of 24 anti-neuronal antibodies that have been associated
with autoimmune encephalitis.
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2.1. Clinical study protocol and assessment
The study started in November 2010. FEP and CHR patients (age 18
to 40 years)were recruited from the catchment area of theHelsinki Uni-
versity Hospital, city of Hyvinkää, and City of Helsinki, Finland. The in-
clusion criteria for the FEP patients were a score of at least 4 in
Unusual thought content or Hallucinations in the Brief Psychiatric Rat-
ing Scale — Extended (BPRS-E) (Ventura et al., 1993) and being fluent
in Finnish. Patients with substance-induced psychotic disorders and
psychotic disorders due to a general medical condition were excluded.
Baseline assessment was conducted as soon as the patient had entered
treatment and was able to give informed consent according to the
treating personnel. Follow-ups included structured diagnostic inter-
views and a review of patient charts and were conducted at two and
12months. CHRwas assessedwith the Structured Interview for Prodro-
mal Syndromes (Miller et al., 2003), and the Criteria of Prodromal Syn-
dromes (COPS) was used to define CHR status.
Controls, matched by age, sex and region of residence, were identi-
fied from the Population Register Center and assessed at baseline and
12monthswith the sameprotocol as the patients. The studywas carried
out in accordance with the Code of Ethics of the World Medical Associ-
ation (Declaration of Helsinki). The study protocol was approved by the
Ethics Committee of the Helsinki University Hospital and by the institu-
tional review boards of the National Institute for Health and Welfare,
Helsinki, Finland. Research permissions were obtained from the Helsin-
ki UniversityHospital and theDepartment of Psychiatry, and theHelsin-
ki City Health Department. All participants gave a written informed
consent.
2.2. Laboratory analytical methods
2.2.1. Blood sampling
A fasting blood sample was collected between 8 am and 10 am.
Serum and plasma samples were immediately aliquoted and stored at
−80 °C with a maximal storage of 4 years. The frozen samples were
all sent at the same time for analysis.
2.2.2. Selection and testing of the antibodies
We screened for anti-brain antibodies that had been described in ei-
ther sporadic primary psychosis or in primary encephalitis with psy-
chotic symptoms. We took into account anti-brain antibodies that
were of potential interest based on genetic association studies in psy-
chosis (Gatt et al., 2015; Nie et al., 2015). Based on a literature review
(OM, JS, BT), we selected isotype IgG antibodies for NMDAR, glutamate
and γ-aminobutyric acid alpha and beta receptors (GABA-a, GABA-b),
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPA), glycine receptor (GlyR), metabotropic glutamate receptor 1
and 5 (mGluR1, mGluR5), anti-Tr/Delta/notch-like epidermal growth
factor-related receptor (DNER), contactin-associated protein-like 2
(CASPR2), myelin oligodendrocyte glycoprotein (MOG), glutamic acid
decarboxylase-65 (GAD65), collapsin Response Mediator Protein 5/
Crossveinless-2 (CV2), aquaporin-4 (AQP4), anti-dipeptidyl-peptidase-
like protein-6 (DPPX), type 1 anti-neuronal nuclear antibody (ANNA-
1, Hu), Ri, Yo, IgLON5,Ma2, zinc finger protein 4 (ZIC4), Rho GTPase-ac-
tivating protein 26, amphiphysin, and recoverin, as well as IgA and IgM
antibodies for dopamine-2-receptor (DRD2).
Antibody analysis was performed blind to case/control status with
an indirect immunofluorescence test of the immunoglobulin (Ig) IgG
isotype, and additionally, IgA and IgM for DRD2. Sera were tested for
the presence of antibodies using biochip mosaics of frozen brain sec-
tions (rat,monkey) and transfectedHEK293 cells expressing the respec-
tive recombinant target antigens (Euroimmun, Germany) as previously
described (Probst et al., 2014). Samples were classified as positive or
negative based onfluorescence intensity of the transfected cells in directcomparison with non-transfected cells and control samples. Endpoint
titers refer to the last dilution showing a detectable degree of fluores-
cence, with 1:10 being the cut-off for positivity. We report immunohis-
tochemistry findings without corresponding positivity in the fixed cell-
based assays, as these could have clinical relevance.
2.3. Statistical analysis
We calculated descriptive statistics for sociodemographic and clini-
cal measures using SPSS Statistics for Windows, Version 22.0.
3. Results
The sociodemographic and clinical characteristics of the sample are
described in Table 1. The only anti-NMDAR positive patient (serum
titer 1:320) was a CHR patient with a major depressive disorder. At
one year, he had not converted to psychosis (See Table 2) but still had
anti-NMDAR autoantibodies (serum titer 1:100) in his blood. After a
thorough evaluation, clinical treatment of encephalitis was not indicat-
ed. All other cell-based assays were negative and there were also no ad-
ditional findings with immunohistochemistry of brain tissues.
Additionally, one patient with a brief psychotic episode was sent for
neurological evaluation due to a clinical suspicion of encephalitis. In
the clinical laboratory testing, hewas found to havemarginally elevated
serum anti-glycine receptor antibodies (titer 1:10). Antibodieswere not
found in his cerebrospinal fluid and encephalitis and neurological dis-
eases were excluded. At the follow-up of 12 months, the patient was
in full remission (Table 2).
4. Discussion
This is the first study to report a person with a CHR for psychosis
having an increased level of anti-NMDAR antibodies. All other mainly
FEP patients showed a negative finding in the tested 24 anti-neuronal
antibodies.
Our results further strengthen the previous view that if brain auto-
antibodies are systematically screened in patients primarily treated for
a psychiatric diagnosis, sporadic cases screen antibody NMDAR positive
(Kayser and Dalmau, 2016). Some samples including FEP patients have
not detected NMDAR antibodies (Masdeu et al., 2012; Masopust et al.,
2015), but others report individuals with positive findings (Lennox et
al., 2017; Pathmanandavel et al., 2015; Steiner et al., 2013; Zandi et al.,
2011). In the largest study so far (228 cases and 105 healthy controls)
seven (3%) patients but no controls had NMDAR antibodies (Lennox et
al., 2017) However, the clinical relevance of the positive findings has
to be confirmed by a thorough examination, and in this sample, none
of the patients had a clinical diagnosis of an encephalitis. Other than
anti-NMDAR antibodies, autoantibodies detected in autoimmune en-
cephalitis seem to remain negative in patients with isolated early psy-
chotic symptoms. Approximately 80% of adults with anti-NMDAR
antibody encephalitis initially manifest behavioral and psychiatric
symptoms (Kayser and Dalmau, 2016). The interest in anti-NMDAR an-
tibodies has been strengthened by increased knowledge about the role
of NMDAR in producing psychosis-like behavior and being involved in
brain processes of etiological importance in psychosis (Carvajal et al.,
2016; Pollak et al., 2016; Rosenthal-Simons et al., 2013). At the same
time, isolated psychiatric symptoms, i.e. psychiatric symptoms without
neurological symptoms, have been present in some patients with anti-
NMDAR encephalitis (Kayser et al., 2013). It is concluded that diagnostic
evaluation in FEP can be focused to those presenting specific neurolog-
ical symptoms (Kayser and Dalmau, 2016).
The strengths of the study include inclusion of FEP and high-risk pa-
tients, comprehensive selection of specific brain receptor antibodies,
and a careful psychiatric evaluation. A limitation of the study was that
no information about non-participants was available to evaluate the
representativeness of the sample. Cerebrospinal fluid analysis, which
Table 1
Characteristics of the sample with 76 cases and 34 controls.
Characteristic Patients, n =
70




Age, mean ± standard deviation 26.3 ± 5.8 25.4 ± 3.5 28.8 ± 6.5
Male, n (%) 46 (65.7%) 5 (83.3%) 19 (55.9%)
Main lifetime diagnosis, n (%)
Schizophrenia 42 (60.0%) 0 0
Schizoaffective disorder 2 (2.9%) 0 0
Bipolar disorder 6 (8.6%) 0 0
Major depressive disorder 2 (2.9%) 1 (16.7%) 6 (17.6%)
Psychosis NOS 13 (18.6%) 1 (16.7%) 0
Other psychotic disorder 5 (7.1%) 0 0
Other psychiatric diagnosis 0 4 (66.7%) 5 (14.7%)
Brief Psychiatric Rating Scale score at baseline, mean ± standard deviation 44.5 ± 10.4 49.0 ± 6.7 25.5 ± 2.9
Social and occupational functioning assessment scale score (Goldman et al., 1992) at baseline, mean ± standard
deviation
39.3 ± 9.2 50.3 ± 7.1 87.1 ± 6.4
Duration of antipsychotic treatment, median, days 27 28 NA
406 O. Mantere et al. / Schizophrenia Research 192 (2018) 404–407would confirm a pathologic process (Kreye et al., 2016), was not
available for patients who did not have antibodies in peripheral blood,
and therefore, false-negative findings are possible. The testing was
performed using fixed cells; testing on living cells might be more
sensitive (Gresa-Arribas et al., 2014) but is difficult to standardize and
lacks suitability for large-scale analyses. The validation of these antibod-
ies has been done only for neurological purposes. Future researchTable 2
Case reports for the two patients where NMDA encephalitis was suspected.
Case 1
Case 1 was a 23-year old university student with a history of recurrent major
depressive episodes. He was referred to the study from outpatient care as a
clinical high-risk patient. He had experiences of paranoid fears and illusions,
while the most difficult symptoms for the patient were depression, anxiety,
insomnia, and a rapid onset of difficulties in thinking and concentrating. He was
nonsmoking and had no history of alcohol or other substance abuse. He met the
criteria for Attenuated Positive Prodromal Syndrome by receiving a score of 4 in
suspiciousness and persecutory ideas. Baseline Social and occupational
functioning assessment scale score was 45, and depressive symptoms were
severe (Beck Depression Inventory score 42). The sample was positive for
anti-NMDAR autoantibodies with serum titer 1:320. Based on this finding, we
contacted the treating personnel and the patient was sent for neurological
examination one year after the anti-NMDAR positive serum sample had been
taken. Serum anti-NMDAR autoantibodies were still present with titer 1:100, but
antibodies were not found in his cerebrospinal fluid and encephalitis and other
neurological diseases were excluded in the examination. Any etiology for the
presence of anti-NMDAR autoantibodies was not found. In the 1-year follow-up,
he no longer met clinical high-risk criteria but had a diagnosis of major
depressive disorder, with a severe major depressive episode without psychotic
features. His level of functioning was low and he had not been able to continue
his studies. He continued to have severe depressive and anxiety symptoms as
well as insomnia despite adequate pharmacological and psychological
treatment.
Case 2
Case 2 was a 34-year-old technician with no previous treatment contact for mental
disorders. Psychotic symptoms, including delusions, disorganized behavior and
marked variation between agitation and motor retardation developed within a
few days. Low-grade fever and headache had preceded other symptoms a few
days earlier. Treatment was started at a neurological department, where the
patient was found to have marginally elevated serum anti-glycine receptor
antibodies (titer 1:10). Antibodies were not found in his cerebrospinal fluid and
thus, encephalitis and other neurological diseases were excluded. C-reactive
protein, lipid, glucose and liver function tests were normal. Laboratory tests for
drug use were negative, and the patient had no history of smoking or current
alcohol use. Intensity of delusions at the most severe phase of the illness was 7
(extremely severe) and intensity of hallucinations 5 (moderately severe) based
on baseline Brief Psychiatric Rating Scale interview. Treatment was continued at
a psychiatric department, and psychotic symptoms resolved within a month. At
the two-month follow-up, the following diagnoses were assigned: a brief
psychotic disorder, with simultaneous social phobia (current) and previous
alcohol abuse, in full remission. At one year, the patient had returned to work in
full remission of psychotic symptoms.should explore the possibility that there are other anti-neuronal
autoantibodies that are specifically related to psychotic disorders.
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